3-[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-1-hydroxy-4-oxo-3-tetradecanoylheptadecan-2-yl]oxy-3-(2-aminoethylamino)-4-[bis(carboxymethyl)amino]-4-(carboxymethyl)hexanedioic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-1-hydroxy-4-oxo-3-tetradecanoylheptadecan-2-yl]oxy-3-(2-aminoethylamino)-4-[bis(carboxymethyl)amino]-4-(carboxymethyl)hexanedioic acid
• 化学式: C₄₇H₈₇N₄O₁₈P
• 分子量: 1027.2
• InChiKey: RXPKWNDYIVXZJE-VTQCWBPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  70
• 可旋转键数：
  50
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  373
• 氢给体数：
  10
• 氢受体数：
  22

文献信息

• MICROPARTICLE COMPOSITIONS
  申请人：Yeh, James Shue-Min

  公开号：EP2934599A1

  公开（公告）日：2015-10-28
• FOCUSED ULTRASOUND HYPERTHERMIA
  申请人：King's College London

  公开号：EP3302702A1

  公开（公告）日：2018-04-11
• [EN] MICROPARTICLE COMPOSITIONS<br/>[FR] COMPOSITIONS DE MICROPARTICULES
  申请人：YEH JAMES SHUE-MIN

  公开号：WO2014096859A1

  公开（公告）日：2014-06-26

  There is provided a microparticle composition suitable for molecular imaging, the composition comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises (i) a phosphatidylcholine lipid: (ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and (iii) an alkoxylated fatty acid.
• [EN] FOCUSED ULTRASOUND HYPERTHERMIA<br/>[FR] HYPERTHERMIE PAR ULTRASONS FOCALISÉS
  申请人：KING'S COLLEGE LONDON

  公开号：WO2016198864A1

  公开（公告）日：2016-12-15

  The invention relates to a hyperthermia (focused ultrasound - FUS) method where an energy source is applied, repeatedly, to a desired part of the body to induce hyperthermia, e.g. using image guidance. Hyperthermia is applied after a drug or biopharmaceutical ( API) and/or their labelled equivalents (theranostics) and/or their drug delivery systems has been administered to the live subject to cause the enhanced tissue distribution and/ or controlled release of the drug, previously encapsulated in thermo-sensitive (lipid nano)particles, to a desired site of the body. Hyperthermia (Ultrasound) is then halted, and the site of interest. Hyperthermia is then applied again using image guidance to monitor drug's accumulation in the tissue. The drug and or the drug delivery system are also labelled (for imaging) to allow real time monitoring and modulation of the API in the human body which can be used to direct and guide the FUS at the site of interest.